Research programme: PEG-somatropin - Bolder BioTechnology

Drug Profile

Research programme: PEG-somatropin - Bolder BioTechnology

Alternative Names: BBT-031; PEG-GH - Bolder BioTechnology; PEG-growth hormone - Bolder BioTechnology; Pegylated-growth hormone - Bolder BioTechnology; Pegylated-somatropin - Bolder BioTechnology

Latest Information Update: 10 Nov 2010

Price : $50

At a glance

  • Originator Bolder BioTechnology
  • Class Growth hormones; Polyethylene glycols; Proteins
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Lipodystrophy; Short stature; Somatotropin deficiency

Most Recent Events

  • 10 Nov 2010 Preclinical development is ongoing in USA
  • 03 Nov 2010 Bolder BioTechnology receives Qualifying Therapeutic Discovery Project grant from the US Department of Health and Human Services for PEG somatropin development in Short stature and Lipodystrophy
  • 14 Aug 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top